Remiges Ventures
19
12M
14
9
0.26
- Areas of investment
Summary
The main office of represented VC is situated in the Cambridge. The company was established in North America in United States.
For fund there is no match between the location of its establishment and the land of its numerous investments - France. Among the various public portfolio startups of the fund, we may underline InFlectis BioScience, Mitoconix Bio The fund has no exact preference in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Biopharma, Life Science. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Remiges Ventures, startups are often financed by Vesalius Biocapital Partners, VC Fonds Technologie Berlin, Lumira Ventures. The meaningful sponsors for the fund in investment in the same round are Vesalius Biocapital Partners, VC Fonds Technologie Berlin, SICAR. In the next rounds fund is usually obtained by Vesalius Biocapital Partners, VC Fonds Technologie Berlin, SICAR.
The fund is constantly included in less than 2 deals per year. The real fund results show that this VC is 63 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Investments analytics
Analytics
- Total investments
- 19
- Lead investments
- 9
- Follow on index
- 0.26
- Investments by industry
- Biotechnology (14)
- Therapeutics (9)
- Health Care (8)
- Medical (8)
- Pharmaceutical (4) Show 4 more
- Investments by region
-
- United States (8)
- Japan (5)
- Germany (2)
- Israel (1)
- France (1) Show 1 more
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 0.89
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Cyrano Therapeutics | 16 Jan 2024 | Health Care, Medical Device, Medical, Therapeutics | Early Stage Venture | 9M | United States, District of Columbia, Washington |
Ethos | 26 Jan 2023 | Cryptocurrency, Blockchain | Seed | 4M | |
Glycomine | 23 Jun 2021 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 35M | United States, California, San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.